In STAT's AACR Recap, reporters Matthew Herper and Angus Chen discussed the mood and highlights of one of the world's largest ...

Q1 2025 Earnings Call Transcript April 30, 2025 Guardant Health, Inc. beats earnings expectations. Reported EPS is $-0.49, ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Gain insights from Arvinas' Q1 2025 earnings call. Explore VEPDEG's regulatory milestones, restructuring plans, and financial strategy for long-term growth.

Shares of Arvinas fell after the biotechnology company ended plans for two Phase 3 trials as part of its collaboration with Pfizer, and said that it would cut about a third of its workforce. The stock ...

Arvinas, along with its partner Pfizer, cancelled plans for a Phase 3 trial combining its PROTAC vepdegestrant with its CDK4 ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first ...

Triple negative breast cancer is aggressive and hard to treat. It also disproportionately affects Black women. A University ...

Folic acid plays a dual role in breast cancer depending on dose and context. While moderate intake may reduce risk, high ...

Breast cancer deaths among women ages 20-49 declined significantly between 2010 and 2020, according to a new study.

Researchers in Dallas want to know if the class of drugs, GIP/GLP-1 receptor agonists, might be a secret weapon in the fight ...